The Outcomes of ICSI Cycles With and Without Letrozole
Status:
Unknown status
Trial end date:
2020-12-30
Target enrollment:
Participant gender:
Summary
A variety of genes working together with ovarian hormones conducts and precisely control the
process of endometrial receptivity and implantation.
Leukemia inhibitory factor and αvβ3 integrin are two markers of implantation with at most
importance. Reports have emphasized that these important biomarkers have a great role during
the process of embryonic implantation.
αvβ3 integrin is one of the adhesion molecules which has a critical role in blastocyst
apposition and attachment. Many studies have demonstrated that abnormal expression of αvβ3
integrin is associated with poor reproductive outcomes. Other studies haven't found a strong
relation between αvβ3 integrin expression and reproductive outcomes Letrozole is an aromatase
inhibitor which has been used in controlled ovarian stimulation especially in women with PCOS
. Data suggests that letrozole addition to gonadotropins during ovarian stimulation protocols
improve the response of the ovaries to FSH in low responders and increase the number of
preovulatory follicles without adversely affect the outcomes.
Letrozole is used as an adjuvant therapy in ovarian stimulation protocols. So this study aims
to evaluate whether the use of letrozole in combination with gonadotropins and GnRH
antagonist is superior to gonadotropins and antagonist alone in women undergoing ICSI
treatment.
Furthermore, both αvβ3 integrin and leukemia inhibitory factor are important markers of
endometrial receptivity and implantation. Therefore, this study aims to assess the
correlation between mid-luteal gene expression of both αvβ3 integrin and leukemia inhibitory
factor and the clinical outcomes of antagonist cycles with or without letrozole.